| Name | Title | Contact Details |
|---|
At Clinipace, a global, full-service contract research organization (CRO), our approach to clinical research is personal. We deliver a level of collaboration and flexibility not possible in a traditional CRO environment. Our personalized services and solutions, local regulatory expertise and therapeutic leadership are designed to face the most difficult industry challenges across all major therapeutic areas including oncology, gastroenterology, nephrology and urology. We strive to improve the way clinical research is performed and impact the future of health care using the most advanced technology and a CHALLENGE ACCEPTED approach. In April 2021, Clinipace & dMed merged creating a differentiated mid-size CRO with the largest Asia-Pacific presence. We are proud to have such a strong group of global investors focused on improving healthcare outcomes and giving sponsors a better CRO choice. dMed`s 2019 acquisition of Target Health commenced the process of building a Next Generation global CRO for biotech and pharmaceutical companies. Our investors have invested over $230M to build the next great global CRO. dMed`s acquisition of Target Health in 2019 began dMed`s evolution from a local to global CRO. Target Health LLC is owned by dMedClinical Co. Ltd., a privately held company that is majority owned, operated, managed, and controlled by a U.S. citizen and foreign entities located in the People`s Republic of China. Dr. Lingshi Tan, is the aforementioned U.S. citizen currently residing in Shanghai, China. Dr. Tan moved to Shanghai (from New York) to become Pfizer`s VP of Worldwide Development Operations, and Chairman and General Manager of Pfizer (China) Research & Development Co. Dr. Tan founded dMed in 2016 to satisfy the local demand for a high quality, responsive, flexible CRO.
Since its beginning in 1902` Cedars-Sinai has evolved to meet the healthcare needs of one of the most diverse regions in the nation` continually setting new standards for quality and innovation in patient care` research` teaching and community service. Today` Cedars-Sinai is widely known for its national leadership in transforming healthcare for the benefit of patients. Cedars-Sinai receives consistent recognition for our excellence. Our awards include; being named one of America`s Best Hospitals by U.S. News & World Report` receiving the National Research Corporation`s Consumer Choice Award 19 years in a row for providing the highest-quality medical care in Los Angeles` achieving the longest-running Magnet designation for nursing excellence in California` and being recognized as The Advisory Board Company`s 2017 Workplace of the Year` an award Cedars-Sinai has won three years in a row. This annual award recognizes hospitals and health systems nationwide that have outstanding levels of employee engagement. Cedars-Sinai is a leader in the clinical care and research of heart disease` cancer and brain disorders` among other areas. Pioneering research achievements include using cardiac stem cells to repair damaged hearts` developing minimally invasive surgical techniques and discovering new types of drugs to target cancer more precisely. Cedars-Sinai also impacts the future of healthcare through education programs that encompass everything from highly competitive medical residency and fellowship programs to a biomedical science and translational medicine PhD program` advanced training for nurses and educational opportunities for allied health professionals. Most notably` Cedars-Sinai demonstrates a longstanding commitment to strengthening the Los Angeles community through wide-ranging programs that improve the health of its most vulnerable residents.
California-based Finesse Solutions brings Silicon Valley technology to bioprocessing. Better performance, integrated intelligence, and plug-and-play bioprocess flexibility are provided by Finesse SmartParts™. Our TruFluor® single-use sensors are unparalleled in the industry. Our G3 Universal™ controllers enable sophisticated cell culture or fermentation recipes to run on any size or brand of vessel. Our TruBio® software provides an easy-to-use interface for upstream bioprocessing that can harmonize old and new equipment, aggregate in-line and off-line data, and electronically facilitate global technology transfer. Finesse enables you to supercharge your R&D laboratory or scale-up to a cGMP SmartFactory with equal ease: we offer complete services, including commissioning and validation.
PCHS of Alaska (Peninsula Community Health Services) is a Soldotna, AK-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
St. John Ambulance is a Gloucester, ON-based company in the Healthcare, Pharmaceuticals, and Biotech sector.